跳轉至內容
Merck
全部照片(1)

Key Documents

688001

Sigma-Aldrich

Y-27632

≥95% (HPLC), liquid, Rho kinase inhibitor, Calbiochem®

同義詞:

InSolution Y-27632, Rho激酶抑制剂VI

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C14H21N3O · 2HCl · xH2O
分子量::
320.26 (anhydrous basis)
分類程式碼代碼:
12352200
NACRES:
NA.77

product name

Y-27632, InSolution, ≥95%, reversible, inhibitor of Rho kinases

品質等級

化驗

≥95% (HPLC)

形狀

liquid

製造商/商標名

Calbiochem®

儲存條件

OK to freeze
protect from light

運輸包裝

wet ice

儲存溫度

−20°C

一般說明

Rho相关蛋白激酶的一种高效、细胞可渗透性、选择性抑制剂(针对p160ROCK(ROCK-I)的Ki= 140 nM)。还可几乎同等高效的抑制ROCK-II。抑制是通过与ATP竞争结合催化亚基而实现的。比p160ROCKε有10至50倍更低的PKC亲和力。即使在高浓度(~100 M)下也不影响p21激活蛋白激酶(PAK)的活性。还可作为肌球蛋白磷酸化和平滑肌收缩的激动剂诱导的Ca2+敏化的一种有效抑制剂(在主动脉环上针对苯肾上腺素诱导的收缩IC50 = 700 nM)。
可提供5 mM (500 µg/296 µl)的Y-27963(目录号 688000)的水溶液。Rho相关蛋白激酶的一种高效、细胞可渗透性、选择性抑制剂(针对p160ROCK(ROCK-I)的Ki= 140 nM)。还可几乎同等高效的抑制ROCK-II。抑制是通过与ATP竞争结合催化亚基而实现的。比p160ROCKε有10至50倍更低的PKC亲和力。即使在高浓度(~100 M)下也不影响p21激活蛋白激酶(PAK)的活性。还可作为肌球蛋白磷酸化和平滑肌收缩的激动剂诱导的Ca2+敏化的一种有效抑制剂(在主动脉环上针对苯肾上腺素诱导的收缩IC50 = 700 nM)。

生化/生理作用

主要靶标
p160ROCK
产物与ATP竞争。
可逆:否
细胞渗透性:是
靶标IC50:针对苯肾上腺素诱导的主动脉条收缩为700 nM
靶标Ki:对于p160ROCK (ROCK-I)为140 nM

包裝

用惰性气体包装

警告

毒性:有害(C)

外觀

5 mM (500 µg/296 µl)Y-27632(目录号688000)的H₂O溶液。

重構

初次融化后,等分并冷冻(-20°C)。

其他說明

Chitaley, K., et al. 2001.Nat. Med.7, 119.
Davies, S.P., et al. 2000.Biochem.J. 351, 95.
Narumiya, S., et al. 2000.Methods Enzymol.325, 273.
Hirose, M., et al. 1999.J. Cell Biol.141, 1625.
Maekawa, M., et al. 1999.Science285, 895.
Uehata, M., et al. 1997.Nature389, 990.

法律資訊

在PCT Application W098/06,433A1的许可和三菱制药田边分公司的许可下进行销售。
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

儲存類別代碼

12 - Non Combustible Liquids

水污染物質分類(WGK)

WGK 2

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號,寫有 ‘Lot’或‘Batch’.。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Sylvia J Gasparini et al.
The Journal of clinical investigation, 132(12) (2022-04-29)
Once human photoreceptors die, they do not regenerate, thus, photoreceptor transplantation has emerged as a potential treatment approach for blinding diseases. Improvements in transplant organization, donor cell maturation, and synaptic connectivity to the host will be critical in advancing this
Aaron C Brown et al.
Methods in molecular biology (Clifton, N.J.), 1926, 63-75 (2019-02-12)
Nephrons differentiate from the cap mesenchyme of the fetal kidney. Nephron progenitor cells that populate the cap mesenchyme efficiently balance self-renewal and epithelial differentiation to enable repeated rounds of nephron formation during development. Here we describe a method to isolate
Rosita Bergström et al.
Methods in molecular biology (Clifton, N.J.), 767, 125-136 (2011-08-09)
Stem cell culture systems that rely on undefined animal-derived components introduce variability to the cultures and complicate their therapeutic use. The derivation of human embryonic stem cells and the development of methods to produce induced pluripotent stem cells combined with
Cory J Smith et al.
Nucleic acids research, 48(9), 5183-5195 (2020-04-22)
To extend the frontier of genome editing and enable editing of repetitive elements of mammalian genomes, we made use of a set of dead-Cas9 base editor (dBE) variants that allow editing at tens of thousands of loci per cell by
Hyunjae Chung et al.
STAR protocols, 3(3), 101617-101617 (2022-08-23)
Induced pluripotent stem cell (iPSC)-derived kidney organoids can be used for disease modeling and drug testing. Here, we describe a protocol to prepare stocks of an infectious clone of SARS-CoV-2 expressing a stable mNeonGreen reporter (icSARS-CoV-2-mNG). We demonstrate the infection

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務